Intravenous fluorescein angiography-associated adverse reactions.

OBJECTIVES

To assess (i) the adverse reactions (ARs) associated with intravenous fluorescein angiography (IVFA); (ii) the relationship between a known history of IVFA-associated AR and ARs on the subsequent IVFA test; and (iii) the dose-response relationship between intravenous sodium fluorescein (NaFl) injection and ARs associated with IVFA.

DESIGN

Retrospective chart review.

PARTICIPANTS

A total of 2247 patients with 3381 consecutive IVFAs between May 2013 and April 2014.

METHODS

Fisher's exact tests or χ tests were used to compare the percentage difference of IVFA-associated ARs for different categorical variables. Logistic regressions were used to assess the relationship between a known history of IVFA-associated AR and any AR(s) on a subsequent IVFA test.

RESULTS

The overall percentage for IVFA-associated ARs was 3.3%. Adjusted for age and sex, patients who had a previous IVFA-associated AR(s) were 6.2 times more likely (adjusted odds ratio 95% CI 3.4-11.2, p < 0.0001) to have an AR compared to those who did not. Among 17 patients who had 2 repeated IVFA tests and an AR on the first IVFA test, the rate of AR on the second test was lower in patients who received a reduced dosage of NaFl (n = 14) compared to those with the standard dosage (n = 3) (35.7% vs 66.7%); however, this finding was not statistically significant (p = 0.5368).

CONCLUSIONS

The rate of IVFA-associated ARs in this study was low. Patients who had a known IVFA-associated AR were more likely to re-experience an AR on a subsequent test compared to those who did not. In addition, a reduced NaFl dose did not significantly reduce the chance of experiencing an AR on a subsequent test, which is likely because of the insufficient power of this comparison.